Repare Therapeutics Inc Down 5.60% To $3.88 After Earnings Beat

Repare Therapeutics Inc (RPTX) said before open Thursday that it lost $0.45 per share in quarter three 2023.

On the revenue line, the company reported $2.2 million, missing estimates by $4.2 million.

In the same quarter a year ago, the company earned $1.71 per share on revenue of $112.5 million.

The stock is down 5.60% to $3.88 after the report.

Repare Therapeutics Inc's profit margins took a hit as earnings fell at a faster pace than revenues.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 30. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.